Advanced Prostate Cancer

Assessment of Cardiovascular Risk with the Use of Androgen Deprivation Therapy for Prostate Cancer

Details
UroToday is excited to host a lecture from a leading cardiologist’s perspective, Dr. Matthew Roe from Duke Clinical Research Institute. Dr. Roe’s discussion features the topics: atherosclerotic plaque formation and plaque instability and incidences of prostate cancer and cardiovascular events. In addition, cardiovascular risks with androgen deprivation therapy, GNRH antagonists and GnRH agonists....

The understanding of personalized androgen deprivation therapy

Details
Thomas Keane, MD provides a presentation concerning the personalization of androgen deprivation with reference to prostate cancer patients. The discussion includes recent data that elevates the discussion on the impact of the agonist or the antagonist used in ADT for men with cardiac conditions, obesity, significant LUTS, and closes on an algorithm for personalized ADT treatment. Biography: Thomas...

Outpatient Urologic Oncology: Primer for the Advanced Practice Provider

Details
Outpatient Urologic Oncology: Primer for the Advanced Practice Provider In this video lecture Anne E Calvaresi, CRNP reviews all Outpatient Urologic Oncology Practice information used in the practices at Jefferson Urology Associates, in Philadelphia, PA. She reviews prostate cancer and bladder cancer in the outpatient setting focusing on the role of the advanced practice professional (NP/PA) and t...

A Conversation on the Role of Chemotherapy in mHSPCa Patients

Details
An interview by E. David Crawford, MD with Neal Shore, MD discussing the role of early chemotherapy use in the treatment of metastatic hormone-sensitive men with prostate cancer. Neal Shore discusses the implications of CHAARTED and more recently STAMPEDE results that provide evidence supporting aggressively treating metastatic hormone-sensitive prostate cancer with docetaxel added to androgen dep...

A Review of Recent Data on Disease-related Outcomes Comparing Agonists and Antagonists for ADT

Details
A Review of Recent Data on Disease-related Outcomes Comparing Agonists and Antagonists for ADT Thomas E. Keane, MD Professor and Chairman of the Department of Urology Medical University of South Carolina, Charleston, SC USA BIOGRAPHY Thomas E. Keane, MBBCh, FRCSI, FACS specializes in managing prostate, bladder, and renal cancers. An avid researcher, Dr. Keane has served as principal investigator o...

Prospective Evaluation of Testosterone Fluctuations During a Transition from Degarelix to Leuprolide

Details
Prospective Evaluation of Testosterone Fluctuations During a Transition of Therapy from Degarelix to Leuprolide in Patients on Androgen Deprivation Therapy Jack Zuckerman, MD Eastern Virginia Medical School Norfolk, Virginia SEE RELATED CONTENT : Prospective evaluation of testosterone fluctuations during a transition of therapy from degarelix to leuprolide in patients on androgen deprivation thera...

Pooled Data from Trials Comparing Degarelix with LHRH Agonist in Men with Advanced Prostate Cancer

Details
Pooled Data from Trials Comparing Degarelix with LHRH Agonist in Men with Advanced Prostate Cancer Laurence Klotz, MD Professor of Surgery, University of Toronto Urologic Oncologist, Sunnybrook Health Sciences Centre SEE RELATED CONTENT : Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist - Abstract Disease control outcomes from analysis of pooled in...

Androgen Deprivation Therapy for Prostate Cancer: Comparing Degarelix to Leuprolide

Details
Androgen Deprivation Therapy for Prostate Cancer: Comparing Head-to-Head Results of Degarelix vs. Leuprolide Thomas E. Keane, MD Professor and Chairman of the Department of Urology Medical University of South Carolina, Charleston, SC USA SEE RELATED CONTENT : Prospective evaluation of testosterone fluctuations during a transition of therapy from degarelix to leuprolide in patients on androgen depr...

Early Treatment for Advanced Prostate Cancer

Details
Early Treatment for Advanced Prostate Cancer Judd W. Moul, MD Dept. of Surgery & Duke Cancer Institute Duke University Durham, NC SEE RELATED CONTENT : Utility of LHRH antagonists for advanced prostate cancer - Abstract Utility of LHRH antagonists for advanced prostate cancer - Full text article The Efficacy and Safety of Degarelix: A 12-Month, Comparative, Randomized, Open-Label, Parallel-Group P...

Experience with Degarelix in the Treatment of Prostate Cancer

Details
Experience with Degarelix in the Treatment of Prostate Cancer Neal D. Shore, MD, FACS Carolina Urologic Research Center Myrtle Beach, SC SEE RELATED CONTENT : Experience with degarelix in the treatment of prostate cancer - Abstract Experience with degarelix in the treatment of prostate cancer - Full text article A phase III extension trial with a 1-Arm crossover from leuprolide to degarelix: Compa...